Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336

Baseline Characteristics of Patients by Sex Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336

Changes in LDL and hs-CRP levels in women and men as stratified by randomization treatment group from baseline to final visit Changes in LDL levels in women (A) and men (B) as stratified by randomization treatment group from baseline to 30 days, 4 months, 8 months, 16 months, and final visit. A greater percent reduction in LDL was observed in the high-dose atorvastatin group than in the standard-dose pravastatin group at all follow-up time points (all P0.0001). Changes in hs-CRP levels in women (C) and men (D) as stratified by randomization treatment group from baseline to 30-days, 4 months, and final visit. The hs-CRP levels were significantly lower in the high-dose atorvastatin than in the standard-dose pravastatin group at all follow-up time points (all P0.003). Hs-CRP indicates high-sensitivity C-reactive protein; LDL, low-density lipoprotein. Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336

Percentage of patients with achieved LDL and hs-CRP target levels Percentage of patients with achieved LDL target levels of 100 mg/dL and 70 mg/dL (A) and with achieved hs-CRP 2 mg/LLDL 70 mg/dL (B) by randomized treatment group as stratified by sex at 30 days and at the final visit. A, All P<0.001 when comparing proportion of patients with achieved target LDL levels with atorvastatin versus pravastatin as stratified by women and men. A greater proportion of men reached target LDL levels with atorvastatin than did women (all P<0.001). In patients receiving pravastatin, the proportion of men and women who achieved target LDL levels was not different (all P<0.13). B, All P<0.015 when comparing proportions of patients with achieved hs-CRPLDL levels with treatment group as stratified by sex. Percentage of patients with achieved LDL target levels of 100 mg/dL and 70 mg/dL (A) and with achieved hs-CRP 2 mg/LLDL 70 mg/dL (B) by randomized treatment group as stratified by sex at 30 days and at the final visit. A, All P<0.001 when comparing proportion of patients with achieved target LDL levels with atorvastatin versus pravastatin as stratified by women and men. A greater proportion of men reached target LDL levels with atorvastatin than did women (all P<0.001). In patients receiving pravastatin, the proportion of men and women who achieved target LDL levels was not different (all P<0.13). B, All P<0.015 when comparing proportions of patients with achieved hs-CRPLDL levels with treatment group as stratified by sex. Q.A. Truong et al. CCQO 2011;4:328-336

Rate of Premature Discontinuation of Statin Therapy and Side Effects of High- Versus Standard-Dose Statin as Stratified by Sex Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336

Kaplan-Meier curves of primary end point by study termination in women (A) and men (B) Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336

Hazard ratios between intensive-dose atorvastatin and standard-dose pravastatin therapy in women and men Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336

Hazard ratios of the primary end point in women treated with intensive lipid-lowering therapy (atorvastatin 80 mg) compared to standard lipid-lowering therapy (pravastatin 40 mg) therapy Hazard ratios of the primary end point in women treated with intensive lipid-lowering therapy (atorvastatin 80 mg) compared to standard lipid-lowering therapy (pravastatin 40 mg) therapy. P-interaction was 0.27 for menopausal status and lipid therapy and 0.75 for ERT and lipid therapy. ERT indicates estrogen replacement therapy. Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336

WHAT THE STUDY ADDS Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:328-336